PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Phenotype | C1140680|ovarian cancer |
| Sentences | 24 |
| PubMedID- 22044796 | Gemcitabine is currently approved for the treatment of ovarian cancer (with carboplatin), breast cancer (with paclitaxel), non-small cell lung cancer (with cisplatin), and pancreatic cancer. |
| PubMedID- 20880789 | Thus, the frequency of synchronous primary ovarian cancer in patients with breast cancer who underwent screening was 0.5%. |
| PubMedID- 24403841 | Interestingly, the authors compared basal-like breast cancer with high-grade serous ovarian cancer, observing many similarities and thus suggesting a possible common therapeutic approach. |
| PubMedID- 20961453 | In some studies, only unaffected mutation-positive women were included and followed up; whilst in others--particularly when examining ovarian cancer risk--women with breast cancer were included. |
| PubMedID- 25848941 | Mutations confer a high risk of breast and ovarian cancer with estimated breast cancer penetrances of 60% for brca1 and 55% for brca2 by age 70 years [73]. |
| PubMedID- 21370594 | Higher incidence of isolated brain metastases in ovarian cancer patients with previous early breast cancer. |
| PubMedID- 23593081 | One pathogenic brca mutation (1/4, 25%) was detected in 4 breast cancer patients with an ovarian cancer family history. |
| PubMedID- 23862292 | Eligible participants fell into 1 of 3 groups: (1) healthy women with at least 1 first-degree relative affected by breast and/or ovarian cancer, (2) women diagnosed with breast cancer at age less than or equal to 50 years; and (3) women diagnosed with breast and/or ovarian cancer at age greater than or equal to 50 years with either 1 first-degree relative or 2 second-degree relatives with breast and/or ovarian cancer. |
| PubMedID- 25762631 | Most sporadic breast and ovarian cancers express low levels of the breast cancer susceptibility gene, brca1. |
| PubMedID- 20569256 | While the cys61gly mutation appeared underrepresented in ovarian cancer as compared with breast cancer cases from the same population (p = 0.01), the 4153dela mutation made a higher contribution to ovarian cancer than to breast cancer (p < 0.01). |
| PubMedID- 24273914 | The first patient, whose mother suffered from breast and ovarian cancer, was diagnosed with left breast cancer in 2004. |
| PubMedID- 25372568 | breast cancer following ovarian cancer in brca mutation carriers. |
| PubMedID- 21939546 | Family b-2002 (figure 4) is a breast/ovarian cancer family, with four breast cancer cases at 43, 43, 52 and 55 years old (mean age: 48.3) and one ovarian cancer at age 52. controlateral breast cancer occurred in two patients (ii-1 and ii-13). |
| PubMedID- 19864120 | Synchronous ovarian cancer in a patient with pleomorphic lobular breast cancer: a therapeutic dilemma. |
| PubMedID- 21559243 | Amongst the asian countries, pakistan has one of the highest rates of breast and ovarian cancer [14] with breast cancer being the most common and ovarian the third most common malignancy amongst pakistani women [15] and the most common cancer of gynecological origin in pakistan [16]. |
| PubMedID- 24853100 | We investigated genetic anticipation of breast or ovarian cancer in patients with familial breast cancer. |
| PubMedID- 25490378 | Recent studies support the following conclusions: first, oral contraceptive use reduces ovarian cancer risk without significantly increasing breast cancer risk, second, salpingo-oophorectomy leads to a reduction in ovarian cancer, breast cancer, and overall mortality for women who are carriers of brca1 and brca2 mutations, and third, the 'ovarian cancers' associated with brca mutations actually include fallopian tube and peritoneal cancer and may have a precursor lesion in the fallopian tube; this observation has prompted the provocative suggestion of removing the fallopian tube to reduce ovarian cancer risk. |
| PubMedID- 25525571 | We will discuss the genetic anomalies and syndromes that may cause ovarian cancers with emphasis on breast cancer type 1/2 mutations. |
| PubMedID- 19900968 | For example, breast cancer clusters with ovarian cancer and prostate cancer. |
| PubMedID- 25138101 | It is difficult to predict what would be the effect of this on the results observed in this study, but in previously published dutch data, the prevalence of breast cancer patients with ovarian cancer in the family was only 2%.37 that same study reported 34% of breast cancer patients to have a family history of breast cancer to the extent of a cgc referral indication;37 higher than the 19% in our study, this difference likely being explained by our younger population. |
| PubMedID- 26197770 | Two patients had breast cancer with or without ovarian cancer as described earlier, while another had a carcinoid tumor of the appendix at the time of ec. |
| PubMedID- 23660117 | We identified the following baseline variables as salient to survey respondents: objective risk for developing ovarian cancer, personal history of breast cancer, perceived risk of developing ovarian cancer, extent of worry about getting ovarian cancer, number of relatives or friends with cancer, and referral for genetic counseling. |
| PubMedID- 24579064 | Contrary to the more convincing outcomes in brca 1/2-related ovarian cancers, the outcomes of brca mutation-related breast cancers are less clear. |
| PubMedID- 24790682 | We observed that all colorectal-, gastric, endometrial-, prostate- and ovarian cancers and 2/3 of breast cancers occurring in carriers of the pms2 mutation displayed msi. |
Page: 1